Comment On Dimebolin (dimebon) Increasing Brain Beta Amyloid In Mouse Models

Main Category: Alzheimer's / Dementia
Also Included In: Neurology / Neuroscience
Article Date: 16 Jul 2009 - 1:00 PDT

email to a friend   printer friendly   opinions  

Dimebolin, originally administered as an antihistamine, has previously been found to help slow the decline of cognitive ability in participants.

This study analysed tau and how dimebolin affects build up of the toxic beta amyloid protein, which is widely believed to be linked to the development of dementia.

This research showed that while dimebolin had a beneficial effect it actually caused an increase of the beta amyloid in mouse models.

'This head scratching research has thrown up surprising results and suggests that while dimebolin provides cognitive benefits it may actually increase levels of toxic beta amyloid in the brain. One possible explanation may be that dimebolin is accelerating the process of beta amyloid development, which may reduce its toxicity. The questions surrounding whether beta amyloid causes nerve death in Alzheimer's or is a bi-product of the process must be addressed by further research.

'One in three people over 65 will die with dementia. Further, more robust research is needed to clarify whether dimebolin is an effective treatment for Alzheimer's in the long term and if these puzzling increases in beta amyloid are also seen in human brains. With the right investment, dementia can be defeated. Alzheimer's Society funds research to improve the lives of people today and to find a cure for tomorrow.'

Professor Clive Ballard
Director of Research
Alzheimer's Society

Reference: Samuel Gandy, Dimebon regulates amyloid beta metabolism in cultured cells, isolated nerve terminals and interstitial fluid of living rodent brain.

Source
Alzheimer's Society

• Additional
• References
• Citations